EffRx grants Ahn-Gook Pharma rights to distribute Binosto in South Korea
Binosto, which provides fracture-risk reduction at the hip & spine, is claimed to be the first and only buffered solution used in the treatment of osteoporosis. EffRx chairman
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Neutralizing a pro-inflammatory molecule known as interleukin-6 (IL-6), the new antibody is expected to represent a significant improvement compared to existing agents that have already entered clinical trials